Evidence map›Paper›PMID 30936429›Full record

ArticleOncogenesis2019

Natural killer cells limit the clearance of senescent lung adenocarcinoma cells.

Kate L Stokes, Virna Cortez-Retamozo, Jonuelle Acosta, Brian Lauderback, Camila Robles-Oteiza, Michelle Cicchini, Mikael J Pittet, David M Feldser

Open access · goldAbstract read
In one paragraph

Article in Oncogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. S-acylation of CaChronic diseases and translational medicine · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kate L StokesDepartment of Cancer Biology, University of Pennsylvania, 421 Curie Blvd., 751 BRB II/III, Philadelphia, PA, 19104-6160, USA.
Virna Cortez-RetamozoCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, 02114, USA.
Jonuelle AcostaCell and Molecular Biology Graduate Program, University of Pennsylvania, 421 Curie Blvd., 751 BRB II/III, Philadelphia, PA, 19104-6160, USA.
Brian LauderbackCell and Molecular Biology Graduate Program, University of Pennsylvania, 421 Curie Blvd., 751 BRB II/III, Philadelphia, PA, 19104-6160, USA.
Camila Robles-OteizaDepartment of Cancer Biology, University of Pennsylvania, 421 Curie Blvd., 751 BRB II/III, Philadelphia, PA, 19104-6160, USA.
Michelle CicchiniDepartment of Cancer Biology, University of Pennsylvania, 421 Curie Blvd., 751 BRB II/III, Philadelphia, PA, 19104-6160, USA.
Mikael J PittetCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, MA, 02114, USA.
David M FeldserDepartment of Cancer Biology, University of Pennsylvania, 421 Curie Blvd., 751 BRB II/III, Philadelphia, PA, 19104-6160, USA. dfeldser@upenn.edu.ORCID http://orcid.org/0000-0001-5975-864X
University of Pennsylvania · USHarvard University · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Translational Research Training Program in Environmental Health SciencesT32ES019851 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Kara A Bernstein, Trevor M Penning · 2012 to 2026
$6.0M
Training In Tumor VirologyT32CA115299 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2006 to 2021
$4.7M
p53-Mediated Tumor Immune SurveillanceR01CA193602 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FELDSER, DAVID · 2015 to 2019
$2.0M
Identifying Mechanisms of p53 and Rb Tumor Suppression In Small Cell Lung CancerR21CA205340 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FELDSER, DAVID · 2016 to 2017
$385k
NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA193602NCI NIH HHS R21 CA205340NCI NIH HHS T32 CA115299NIEHS NIH HHS T32 ES019851U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) P30-CA016520U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) T32CA115299U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) T32ES019851
6 · The paper itself

Abstract

Senescence is an important p53-controlled tumor suppressor program that not only opposes the proliferation of cancer cells but also promotes their immune-mediated clearance in certain contexts. In hepatocellular cancer, p53 induction promotes an innate immune cell-mediated clearance of senescent cells wherein natural killer (NK) cells seem to play the primary sentinel role. Whether NK cells also surveil cancer cells in other tumor types when p53 is activated to promote a senescence response is unknown. To identify the role that NK and other innate immune cell types have on the surveillance and destruction of lung adenocarcinoma cells, we developed an orthotopic transplantation model where p53 gene function could be restored to induce senescence after successful engraftment of tumor cells in the mouse lung. Contrary to precedent, we found that NK cells actually limited the efficient clearance of tumor cells from the mouse lung after p53 restoration. Instead, activation of p53 induced the infiltration of monocytes, neutrophils, and interstitial macrophages. Loss of NK cells further promoted expansion of these inflammatory cell types and tumor clearance after p53 restoration. These observations suggest that NK cell responses to p53 activation in lung adenocarcinoma is distinct from those found in other tumor types and that diverse innate immune cell populations may play context-dependent roles during tumor immune surveillance. Further, our data provide an impetus to understand the broader mechanisms that regulate cancer cell destruction by multiple cell types of the innate immune system and distinct cancer contexts.

Identifiers

PMID30936429
PMCPMC6443683
OpenAlexW2929329526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.